Huang Shan Shi

Researchers are establishing a standardized clinical information database for liver cancer patients through a collaborative effort led by the Department of Hepatobiliary Surgery at the First Affiliated Hospital of the University of Science and Technology of China (USTC). This database aims to support high-quality real-world clinical studies and research on hepatocellular carcinoma and related liver cancers. Participants may receive routine treatments such as surgical operations including resection, ablation, transarterial chemoembolization (TACE), and hepatic arterial infusion chemotherapy (HAIC). They might also be treated with various anti-tumor drugs including immunologic, targeted, and chemotherapy medications. Treatments and clinical data are collected to enrich the database for future research. During the study, participants will provide blood samples and postoperative pathology residual samples and will be followed over time to monitor their health and treatment outcomes. The primary outcome measured is overall survival over 10 years. Participants must be willing to comply with follow-up visits and provide informed consent, ensuring comprehensive data collection for long-term analysis.

Gallstones are a common condition in China, affecting about 15% of the population, or approximately 210 million people. Acute cholecystitis, which is inflammation of the gallbladder, often occurs as a complication of gallstones and can be life-threatening if untreated. This research evaluates single-incision laparoscopic cholecystectomy (SILC) for treating acute cholecystitis, focusing on its effects on postoperative quality of life, pain, scar-related complications, and safety compared to traditional methods. Participants will undergo either SILC or traditional surgical approaches such as open cholecystectomy. If the surgery becomes too difficult to complete using the planned method, both groups may be switched to open cholecystectomy. The study aims to establish standardized procedures for SILC by assessing its impact on recovery and complications. During the study, researchers will track participants' recovery and quality of life, specifically measuring the time it takes to return to normal life over a three-year period. Postoperative pain, scar evaluations, and any complications will be monitored to understand the effects of the surgical methods. Safety and long-term outcomes will also be observed to provide comprehensive information about the treatments.

This is a multicenter, randomized, double-blind, placebo-controlled, exploratory Phase II clinical trial. The goal of this clinical trial is to assess the safety and efficacy of edaravone dexborneol sublingual tablets for post-stroke cognitive impairment in patients with acute ischemic stroke. Participants will be required to receive 24 weeks treatment of edaravone dexborneol sublingual tablets or placebo during this study. The safety and efficacy endpoints will be compared in the patients with edaravone dexborneol sublingual tablets or placebo.

Researchers are investigating whether adding endovascular therapy (EVT) to the best medical management improves outcomes for adults who have had a minor stroke caused by a large blood vessel blockage in the brain and who experience worsening neurological symptoms more than 24 hours after stroke onset. The study focuses on patients with an ischemic stroke affecting the anterior circulation and evaluates the safety and effectiveness of EVT in this late time window. The study enrolls about 272 patients aged 18 years or older who have a minor stroke with a National Institutes of Health Stroke Scale (NIHSS) score less than 6, evidence of large vessel occlusion, and symptom progression within 7 days. Participants are randomly assigned to receive either best medical management alone, which includes monitoring vital signs and standard drug therapies, or best medical management plus EVT, which may involve mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty, or stenting. The study involves seven visits from randomization through 90 days to monitor progress. During the study, participants undergo assessments of neurological function, imaging tests, laboratory studies, and symptom evaluations at multiple time points up to 90 days. The primary outcome measured is the proportion of patients achieving good clinical outcomes 90 days after randomization based on a modified Rankin Scale score of 0 to 2. Safety is closely monitored by a Data and Safety Monitoring Board, and the trial follows ethical guidelines and regulatory standards. The study is expected to run from December 2023 to December 2025 at about 30 centers in China.